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ABSTRACT
Pharmacological Characterization of Sigma-2 Preferring Compounds: Implications
in Cocaine-induced Behaviors
Bahar Noorbakhsh
Cocaine is a powerful psychostimulant that is highly abused by 1.9 million people in
the United States. It accounts for more emergency department visits than any other illicit
drug. Even with the high rate of cocaine abuse, no FDA approved pharmacological
treatments exist. Many attempts at finding a pharmacotherapy for cocaine abuse and
addiction have been made, but proven unsuccessful. Cocaine is known to bind sigma
receptors at physiologically relevant concentrations, deeming them potential targets for
cocaine pharmacotherapies and helping to elucidate the actions of cocaine. Two subtypes
of sigma receptors have been described, sigma-1 and sigma-2. Minimal information is
known about the function of sigma-2 receptors in relationship to cocaine-induced effects.
This is attributed to the inability to clone the subtype and the absence of highly selective
ligands. In the present study four novel compounds (CM699, CM398, CM777 and
CM775) were found through radioligand binding assays, in rat brain homogenates and
liver P2 membrane (with the exception of opioid receptors in CHO cells), to possess
substantially high affinities for sigma-2 receptors versus sigma-1 and non-sigma receptor
sites. Behavioral studies, performed in male, Swiss-Webster mice, showed that
pretreatment of CM398, CM777 and CM775 to a convulsive or stimulatory locomotor
dose of cocaine led to significant attenuation of cocaine-induced convulsions and
hyperactivity. Additionally, administration of pretreatment doses of CM699 to nonconvulsive doses of cocaine led to the occurrence or exacerbation of cocaine-induced
convulsions. The availability of these sigma-2 receptor preferring compounds provide
pharmacological tools to elucidate the relationship between sigma-2 receptors and
cocaine effects. Furthermore, these ligands present promising putative pharmacological
treatments for cocaine abuse and addiction.
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I. BACKGROUND
A. Cocaine
Cocaine is a powerful and addictive stimulant that is highly abused in the United States.
An estimated 1.4 million people in the United States meet the Diagnostic and Statistical
Manual of Mental Disorders criteria for cocaine dependence or abuse (NIDA, 2010).
Furthermore, cocaine contributes to 1 in 4 emergency department drug abuse related
mentions (NIDA, 2010). Moreover, healthcare and loss of productivity costs cause
cocaine use to be a huge economic burden in the United States (Office of National Drug
Control Policy, 2004).
The desirable, acute effects of cocaine include: euphoria, energy and mental alertness.
Furthermore, cocaine results in decreases in the need for food and sleep (NIDA, 2010).
These properties contribute to the addictive nature of the drug. Yet, there are also serious
medical complications caused by cocaine use. Being that it causes vasoconstriction,
cocaine can result in cardiovascular complications like arrhythmias, hemorrhaging and
heart attacks. Furthermore seizures, coma, strokes and convulsions have been seen with
cocaine use. Fatality from this drug is often a result of cardiac and respiratory arrest
(NIDA, 2010; Narayanan et al., 2011).
The ‘dopamine hypothesis’ is the ideology that cocaine primarily produces its’ rewarding
effects through the mesolimbic and mesocortical dopamine pathways in the nucleus
accumbens, ventral tegmental area and front cortex (Carroll et al., 1999). Here cocaine
acts as an indirect agonist, binding to DAT and preventing the reuptake of dopamine.
This results in an increased dopamine concentration in the synapse leading to a prolonged
and increased signal (Carroll et al., 1999). This ideology was further supported by the
ability of dopamine reuptake inhibitors and dopamine receptor agonists to sustain cocaine
self-administration in animals (Hiranita, 2010). Conversely, dopamine receptors
antagonists were able to attenuate some of cocaine’s behavioral effects in animals
(Carroll et al., 1999). Thus, DAT became the focus in research of putative
pharmacotherapies for cocaine use and abuse.
Early cocaine abuse pharmacotherapy research was based around the ‘dopamine
hypothesis. Many compounds were developed in the hopes of attenuating cocaine effects
by blocking cocaine reuptake using dopamine uptake inhibitors or DAT antagonists
(Carroll et al., 1999). Yet, many of these compounds actually displayed the opposite
outcome by producing cocaine-like effects (Narayanan et al., 2011). Furthermore, studies
using DAT knockdown and knockout showed that animals still exhibited the rewarding
effects of cocaine (Itzhak et al., 1997; Tilley et al., 2009). Another putative
pharmacotherapy studied was dopamine receptor antagonists but, unfortunately, these
compounds showed limit success largely due to the occurrence of adverse side effects
(Carroll et al., 1999). The lack of success for a pharmacotherapy targeting the
dopaminergic system led to the focus of other targets, including serotonergic,
noradrenergic, cholinergic, GABAergic, glutamatergic, cannabinoid and opioid systems,
which have all shown to bind to cocaine (Narayanan et al., 2011). Unfortunately, these
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systems still showed limited or no clinical success in treating cocaine’s addictive and
rewarding properties due to low efficacy and adverse side effects (Narayanan et al.,
2011).
Considering there still remains no FDA approved pharmacotherapies for cocaine abuse
and addiction, there is still a need to look elsewhere for potential therapeutic targets. One
receptor system that has shown to interact with cocaine at physiologically relevant
concentrations is sigma receptors. The discovery of this interaction laid the groundwork
for research assessing the potential of sigma receptors as targets for putative cocaine
abuse pharmacotherapies (Sharkey et al., 1988).
B. Sigma Receptors
Sigma receptors were first reported in 1976 by Martin and colleagues while researching
the effects of the benzomorphan, N-allyl-normetazocine (SKF 10,047) in morphinedependent and non-dependent chronic spinal dogs (Martin et al., 1976). The compound
produced psychomimetic effects independent of interactions with mu (µ) and kappa (κ)
opioid receptors (Martin et al., 1976). This resulted in the receptor’s characterization as a
sigma (σ) opioid subtype (Martin et al., 1976).
Further studies using (+) and (-) benzomorphan isomers showed that the sigma subtype
displayed preferential affinity for the dextrorotatory rather than the levorotatory isomers,
opposite of what is seen with opioid receptors (Su, 1982) Thus, it was determined that the
sigma receptor was actually not an opioid receptor subtype (Su, 1982). Also, because
(+)-SKF 10,047 bound to phencyclidine (PCP) sites found in N-methyl-D-aspartate
(NMDA) glutamate receptors, it was thought that sigma receptors and these NMDA
receptor/PCP binding site were identical (Mendelsohn et al., 1985). However, this proved
incorrect due to selective NMDA ligands, such as MK-801, ((+)-5-methyl-10,11-dihydro5H-dibenzo[a,d]cyclohepten-5,10-imine maleate)) only partially displacing (+)-SKF 10,
047 bound to the PCP site. This indicated that (+)-SKF 10,047 was binding to another
site (Wong et al., 1988). These data along with further radioligand binding studies
showed unique drug selectivity binding patterns that confirmed the existence of a novel
and unique receptor, deemed sigma receptors (Su, 1982).
Radioligand binding studies, using selective sigma ligands, helped further characterize
sigma receptors. Differences in benzomorphan (+)/(-)-isomer binding affinities and
molecular weight helped differentiate two sigma receptor subtypes, deemed sigma-1 and
sigma-2 (Hellewell and Bowen, 1990). The two subtypes are not only distinguished by
their drug selectivity and molecular weight but also function, tissue distribution and
subcellular localization (Guitart et al., 2004).
B.1. Sigma-1 Receptors
Sigma-1 receptors are 25-29 kDa in size (Matsumoto et al., 2003). They have been
cloned from various species, such as rodents and humans (Hanner et al., 1996; Kekuda et
al., 1996). From the 223 amino acid sequence it has been characterized as unique protein
unlike any other known receptors and is highly conserved across species and tissue types
(Matsumoto, 2007). Sigma-1 receptors are highly expressed in brain, heart, liver, spleen
and GI tract tissues (Matsumoto, 2007). Though endogeneous ligands for sigma receptors
have been proposed, such as progesterone and other neuroactive steroids, none have been
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confirmed (Matsumoto, 2007). Within the cell it is located on plasma membrane,
mitochondrial membrane and the endoplasmic reticulm (Guitart et al., 2004).
Upon activation sigma-1 receptors translocate from the endoplasmic reticulm to the
plasma or nuclear membrane and form protein-protein interactions (Hayashi and Su,
2003; Hayashi and Su, 2007). They can then modulate signaling molecules, ion channels
and G-protein-coupled receptors (GPCRs) (Matsumoto, 2009). Sigma-1 receptors have
been implicated in the regulation of potassium channels, IP3-mediated calcium signaling,
dopamine synthesis and release, acetylcholine synthesis and release, NMDA-mediated
neurotransmitter release and muscarinic-mediated phosphoinositide turnover (Bowen,
2000; Hayashi and Su, 2007).
Initially sigma-1 receptors were elucidated through the use of highly selective ligands.
The compound (+)-pentazocine is a truly selective sigma-1 agonist, amongst others,
commonly used to study sigma-1 functions (Bowen et al., 1993). While compounds such
as BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine) and NE-100 (4methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzene ethanamine) represent selective
antagonists, along with many others, for sigma-1 receptors (Matsumoto et al., 1995;
Chaki et al., 1994).
A major breakthrough for sigma receptor research was the first successful cloning of
sigma-1 from guinea pig liver and subsequent mammalian membrane, which provided
information about the structure and function of sigma-1 receptors (Hanner et al., 1996;
Kekuda et al., 1996). Also, the availability of antisense oligodeoxynucleotides, sequencespecific antibodies and sigma-1 knockout mice has further aided in the characterization of
sigma-1 receptor functions (Matsumoto, 2007).
B.2. Sigma-2 Receptors
In contrast to sigma-1, much less is known about the sigma-2 receptor subtype. The
receptor has not yet been cloned but is known to be 18-22 kDa in size (Matsumoto et al.,
2003). Recently, through the labeling of sigma-2 receptors with novel sigma-2 ligands, it
has been purported that the sigma-2 receptor binding site is located in the progesterone
receptor membrane complex 1 (PGRMC1) (Xu et al., 2011). The findings of this study
are promising in helping provide molecular biological tools to studying sigma-2 binding
sites. Nonetheless, the labeling ligands used in the study are selective for sigma-2 versus
sigma-1 receptors. However the selectivity and affinity of these ligands for non-sigma
sites is unknown. Therefore, this causes uncertainty as to whether the binding site in
PGRMC1 is indeed sigma-2 or perhaps a different site possessing high affinity and
selectivity for the labeling ligand. Thus, to validate the PGRMC1 binding,
characterization of sigma-2 labeling ligands that have high binding affinity as well as
high selectivity for sigma-2 versus sigma-1 and non-sigma receptor sites need to be used.
Sigma-2 receptors are highly expressed in brain, liver and gastrointestinal tract tissue
while their cellular location includes mitochondria, endoplasmic reticulum, lysosomes
and plasma membranes (Matsumoto, 2007; Matsumoto, 2009). Furthermore, sigma-2
receptors are present in high numbers in tumor and tumor cell lines, such as
neuroblastomas, gliomas, melanomas, breast, prostate, lung and leukemia, within
12

membrane lipid rafts (Gebreselassi and Bowen, 2004; Crawford and Bowen, 2002).
Though sigma-1 receptors have also been seen in these cell lines, sigma-2 is much more
highly expressed (Crawford and Bowen, 2002). MCF-7, a breast tumor cell line, is
thought to express sigma-2 but not sigma-1 receptors (Crawford and Bowen, 2002).
Moreover, levels of sigma-2 receptors are 10 times greater in rapidly dividing versus
quiescent cells (Bowen, 2007). This is in accordance to the known function of sigma-2
receptors in regulating cell proliferation and maintaining cell viability (Vilner and
Bowen, 1999).
There are two ways sigma-2 receptors regulate the release of intracellular calcium, which
is involved in modulation of cell proliferation and cytotoxicity (Vilner and Bowen, 1999).
First, upon activation it causes a rapid, transient release of calcium from the endoplasmic
reticulm (Vilner and Bowen, 1999). Second, extended activation of sigma-2 leads to a
sustained release of intracellular calcium from the mitochondria that is subsequently
implicated in the onset of apoptosis (Bowen, 2000). Also, activation of sigma-2 receptors
causes increases in ceramide, a sphingolipid (Crawford et al., 2002). Ceramide can
function to stimulate cell proliferation or induce apoptosis, though it is usually associated
with the latter (Bowen, 2007). It is hypothesized sigma-2 results in the formation of
ceramide through activation of enzymes that acylate sphingosine which can then go on to
mediate actions involved in apoptosis (Bowen, 2007). Furthermore, it has been suggested
that this activated enzyme hydrolyzes sphingomyelin forming SPC (Kita et al., 2001).
SPC then aids in promoting cell proliferation and survival (Bowen, 2007). These findings
suggest that sigma-2 receptors are involved in regulating cell life and death.
Due to its presence in tumor cell lines and involvement in the cell cycle, sigma-2
receptors represent potential therapeutic uses in cancer (Bowen, 2007). They have been
studied as potential chemotherapies (Crawford and Bowen, 2002). Studies have shown
tumor cells that develop resistance to antineoplastic agents do not show this effect with
the use of sigma-2 receptor ligands, giving promise to potential chemotherapeutic agents
(Stein et al., 2004). Another therapeutic use of sigma-2 is as a non-invasive tumorimaging agent because of their high expression in tumor cell lines (Hashimoto and
Ishiwata, 2006).
Though still unclear, sigma-2 receptors are involved in the effects of drug abuse, similar
to sigma-1 receptors (Narayanan et al., 2011). Sigma-2 receptor activation has shown to
enhance dopamine release caused by the presence of amphetamine (Izenwasser et al.,
1998). One hypothesized mechanism is activation of the receptor results in the reversal of
membrane transporters causing more dopamine to be taken out of the cell (Izenwasser et
al., 1998). Another explanation is activation of sigma-2 receptors increase amphetamine
uptake into intracellular vesicles by the regulation of intracellular calcium pools
(Izenwasser et al., 1998). Much remains to be elucidated about sigma-2 involvement in
dopamine regulation of amphetamine in addition to other drugs, like cocaine, that utilize
dopaminergic systems.
The paucity in molecular and pharmacological tools makes it difficult to study the effects
of sigma-2 receptors in the actions of abused drugs. It is crucial to study both sigma
receptor subtypes when targeting them for putative drug abuse pharmacotherapies. This
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will help provide information in the pharmaceutical design of the drugs as to which sigma
subtype(s) should/should not be targeted for the most efficacious outcome. Also, studying
the effects of each sigma subtypes will aid with developing side-effect profiles of
potential pharmacological compounds.
C. Sigma Receptors and Cocaine
Cocaine has a micromolar binding affinity for sigma receptors and, as aforementioned,
this interaction of sigma and cocaine at physiologically relevant concentrations laid the
groundwork for research involving the receptors as targets for putative cocaine abuse
pharmacotherapies (Sharkey et al., 1988). To block or attenuate the effects of cocaine, a
sigma receptor antagonist is needed (with sigma receptor agonists would exacerbate or
potentiate the effects) (Matsumoto, 2003).
Many studies looking at the involvement of sigma-1 receptors in cocaine effects have
been conducted. Sigma-1 receptor antagonists have been shown to significantly decrease
cocaine-induced convulsions and locomotor hyperactivity in animals (Robson et al.,
2011). Furthermore, many of these antagonists were even able to reduce lethality from
cocaine overdose in animals (Matsumoto et al., 2003). The involvement of sigma-1
receptors in these effects was validated using antisense oligonucleotides, which reduced
the number of sigma-1 receptors by 40% (Matsumoto et al., 2003). This decrease also
resulted in attenuation of cocaine-induced convulsions and hyperactivity (Matsumoto et
al., 2002). Therefore, sigma-1 antagonists may serve as promising agents in
pharmacotherapies for cocaine toxicity. The effect of sigma-1 in the rewarding properties
of cocaine has also been evaluated. Conditioned place preference is a behavioral
paradigm that measures the rewarding effects of cocaine from the ideology that animals
will return and spend more time in environments in which they receive cocaine (Maurice
et al., 2002). Administrations of sigma-1 antagonists have shown to attenuate cocaineinduced place preference (Romieu et al., 2000). Thus, in addition to toxicity, sigma-1
antagonists may also serve as potential pharmacological treatments for cocaine’s
rewarding actions.
There is a lack of molecular biological tools for evaluating sigma-2 receptors, less is
known about the role of this subtype in the effects of cocaine. Similar to sigma-1
antagonists, it has also been observed that sigma-2 receptor antagonists significantly
attenuate cocaine-induced convulsions and hyperactivity (Matsumoto et al., 2007).
Though the precise mechanism of sigma-2 in cocaine-induced hyperactivity remains
unclear; it is thought that the receptor modulates dopaminergic systems involved in
cocaine’s locomotor actions (Bastianetto et al., 1995). This ideology is largely based on
the preference of DTG to act on dopaminergic systems in the nigro-striatal pathway.
Additionally, a strong correlation between circling behavior and a ligand’s affinity for
sigma-2 receptors has been reported (Walker et al., 1993). Yet, the relatively low
selectivity of these ligands used for sigma-2 versus sigma-1 and no methods for
knockdown or knockout specifically for sigma-2, causes uncertainty in whether effects on
cocaine behaviors is due to the specific involvement of sigma-2 receptors.
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D. Sigma-2 Receptor Ligands
One of the issues in studying the role of sigma-2 receptors is the paucity of selective
pharmacological ligands. Functionality of ligands was characterized using the
pharmacological terms for an agonist and antagonist. An agonist is a ligand causing a
response at the receptor, while an antagonist inhibits the effects caused by an agonist yet
has no effect alone. Previous literature has reported the development of purposed sigma-2
selective ligands. Two of these compounds that have been studied in regards to cocaine
effects are sigma-2 antagonists (±)-SM21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate)
and UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine). Though these compounds bound
to sigma-2 receptors, they displayed a low selectivity, <50-fold, and affinity for sigma-2
receptors versus sigma-1 receptors (Matsumoto et al., 2007). Previously identified
selective sigma-2 putative agonists, CB-64 ((+)-1R,5R-(E)-8-benzylidene-5-(3hydroxyphenyl)-2-methylmorphan-7- one) and CB-184 ((+)-1R,5R-(E)-8-(3,4dichlorobenzylidene)-5-(3-hydroxyphenyl)-2-methylmorphan-7 – one), displayed high
selectivity, >100-fold and >500-fold respectively, yet showed only moderate binding
affinity for sigma-2 receptors and exhibited binding to opioid receptors (Bowen et al.,
1995; Newman and Coop, 2007). Few sigma-2 selective compounds, like RHM-4 (N-(4(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-fluoroethoxy)-5-iodo-3methoxybenzamide) and WC-59 (9-(4-(2-fluoroethyl)benzyl)-9-azabicyclo[3.3.1]nonan3-yl-2-methoxy-5-methyl-phenylcarbamate), have exhibited substantial selectivity,
>1000-fold, for sigma-2 over sigma-1 receptors (Tu et al., 2007; Chu et al., 2007). Yet,
no data exhibiting their affinities for non-sigma receptor sites have been published,
causing question as to whether these compounds’ effects are a result of binding to sigma2 receptors. Thus, the importance of using compounds that have high binding affinity as
well as high selectivity for sigma-2 versus sigma-1 receptors and non-sigma receptor sites
when studying the subtype is imperative.
Our study utilized SAR assessments to synthesize a series of compounds in the hopes of
identifying selective sigma-2 receptor ligands. All of the novel compounds were
benzimidazolinone derivatives. This rationale was based on their preferential affinity and
selectivity for sigma-2 receptors as compared to benzoxazolones (Mesangeau et al.,
2008). The compounds also all contained a four-methylene spacer that proved to
maximize sigma-2 versus sigma-1 receptor selectivity (Berardi et al., 2004). To further
identify changes in ligand receptor affinity, three positions were substituted, R1, R2 and
R3, amongst the derivatives. R1 consisted of various cyclohexylpiperazine moieties
hypothesized to be a contributing factor to sigma-2 receptor selectivity. Substitutions in
the R2 and R3 position primarily evaluated the effects of lipophilicity on selectivity
(Mesangeau et al., 2008) (Fig. 1). Radioligand binding studies on the novel compounds
determined selective, >100-fold, sigma-2 receptors ligands that were then used in
subsequent studies.
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Fig. 1. Functional Group Substitutions
Different functional groups were substituted at the R1, R2 and R3 positions in order to
evaluate the effects on sigma-2 receptor affinity and selectivity.
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E. Statement of Problem
Sigma receptors serve as a promising target in the development of cocaine
pharmacotherapies. Yet, a factor widely hindering this is the ambiguity of sigma-2
receptor involvement in cocaine’s actions. This is largely due to a lack of sigma-2
receptor pharmacological tools. Previous literature has reported the development of
purported sigma-2 selective ligands yet various shortcomings can be seen. First being,
that some of these compounds displayed a low selectivity for sigma-2 receptors versus
sigma-1 receptors (Matsumoto et al., 2007b; Mesangeau et al 2008). A second problem
being that even with compounds displaying high sigma-2 versus sigma-1 selectivity, only
moderate binding affinities for the sigma-2 receptor was exhibited. Lastly, many of these
purported sigma-2 selective ligands lack data exhibiting their affinities for non-sigma
receptor sites thus causing question as to whether these compounds’ effects are in fact
due to specific sigma-2 receptor binding (Tu et al., 2007; Chu et al., 2007). Thus, it is
imperative to synthesize compounds that are both highly selective for sigma-2 receptors
versus sigma-1 and non-sigma receptors in addition to having high affinity for the
receptor subtype itself in order to elucidate the receptors’ effect in cocaine actions.
F. Specific Aims
1. To determine the sigma-2 receptor affinity and selectivity of novel sigma receptor
compounds.
Sigma receptor binding affinities, of the novel sigma-2 ligands and reference compounds,
will be established from brain tissue as well as liver tissue. The values will also be
correlated to one another. This will be beneficial for multiple reasons:
i. Allows determination of the novel sigma-2 ligands’ binding affinities for sigma
and non-sigma receptors
ii. Enables comparison of the novel sigma-2 ligands binding affinities across
organ tissue: Sigma-2 receptors reside in lipid rafts (Gebreselassi, 2004).
Previous studies demonstrated that due to sigma-2 receptor localization in lipid
rafts, binding affinity of ligands for sigma-2 could be influenced (Fishback,
2011). This is hypothesized to be a result of variations in lipid compositions and
associated proteins in different lipid rafts interfering with compounds’ ability to
bind to the receptor (Fishback, 2011). Therefore, using both brain and liver
membrane will allow comparison of sigma-2 receptor affinity ratios. If the ratio is
maintained across tissue, selectivity of the compounds’ for sigma-2 receptors can
more confidently be concluded.
iii. Provides similar molecular environment for comparing sigma-1 and -2
receptors: Due to brain tissue having lower concentrations of sigma-2 than sigma1 receptors the common practice is to use liver membrane when studying the
sigma-2 subtype. Since high concentrations of sigma-1 receptors are also seen in
liver (Matsumoto, 2007), this tissue can be used when studying either subtypes,
decreasing the likelihood data generated is an artifact of different tissues being
used.
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2. To determine the effects of novel sigma-2 receptor ligands in cocaine-induced
actions.
i. Cocaine-induced Convulsion Studies: The effects of the novel ligands on acute
cocaine toxicity will be measured through the cocaine-induced convulsion
behavioral paradigm. The data from this study has potential clinical significance
with regards to cocaine overdose in humans.
Furthermore, this study provides a quick and easy initial screening to observe
functionality of the novel ligands. An antagonist will block, while an agonist will
elicit, cocaine-induced convulsions. Previous literature has shown sigma receptor
antagonists to attenuate cocaine-induced convulsions (Katz et al., 2011).
Conversely, sigma receptor agonists have shown to cause convulsions at low
doses of cocaine that administered alone show no convulsive effects (Katz et al.,
2011). Additionally, sigma agonists worsened cocaine toxicity by causing
lethality in response to doses of cocaine that given alone are not lethal
(Matsumoto et al., 2003). These agonistic outcomes produced a leftward shift in
cocaine-induced convulsion dose response curves (Matsumoto et al., 2002).
ii. Locomotor Activity Studies: The impact of the novel ligands on cocaine
psychomotor stimulant effects will be measured with locomotor activity
behavioral tests. This paradigm reflects the stimulant actions seen in persons upon
the administration of cocaine. These stimulant actions contribute to the drug’s
rewarding properties. Thus, locomotor activity will provide additional information
for the sigma receptor compounds being putative cocaine pharmacotherapies.
Locomotor activity studies will provide an easy and fairly quick initial screen of
ligand functionality which can subsequently help choose compounds to include in
more time consuming and intricate cocaine behavioral tests (Matsumoto et al.,
2007). Earlier studies have characterized sigma antagonists blocking and agonists
exacerbating, cocaine-induced locomotor hyperactivity (Katz et al., 2011).

II. MATERIALS AND METHODS
A. Drugs and Chemicals
CM398 (1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H benzo[d]imidazol-2(3H)-one), CM699 (1-(4-(3H-spiro[isobenzofuran-1,4’-piperidin]-1’yl)butyl)-3-methyl-1H -benzo[d]imidazol-2(3H)-one), CM77 (1-(4-(4-(4flurophenyl)piperazin-1-yl)butyl)-3-pentyl-1H -benzo[d]imidazol-2(3H)-one) and
CM775 (1-(4-(4-(4-flurophenyl)piperazin-1-yl)butyl)-3-propyl-1H -benzo[d]imidazol2(3H)-one) were synthesized at the University of Mississippi (University, MS). The
structures of these novel ligands are shown in Fig. 2. Cocaine hydrochloride was obtained
from Sigma-Aldrich (St. Louis, MO). The radioligands were procured from Perkin Elmer
(Boston, MA) and all other chemicals used were obtained from standard commercial
suppliers (Sigma-Aldrich, Milwaukee, WI).
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Solutions of the compounds’ tested in radioligand binding assays were prepared by
diluting with deionized water or DMSO, depending on the compounds’ solubility
properties. While, the receptors were labeled with radioligand solutions prepared with 50
nM Tris buffer. In the behavioral studies using mice, all of the compound and drug
preparations were diluted using saline

Fig. 2. Chemical structures of novel ligands.
A, CM398 (1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1Hbenzo[d]imidazol-2(3H)-one), B, CM699 (1-(4-(3H-spiro[isobenzofuran-1,4’-piperidin]1’-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one), C, CM775 (1-(4-(4-(4flurophenyl)piperazin-1-yl)butyl)-3-pentyl-1H-benzo[d]imidazol-2(3H)-one) and D,
CM777 (1-(4-(4-(4-flurophenyl)piperazin-1-yl)butyl)-3-propyl-1H-benzo[d]imidazol2(3H)-one).
B. Animals
Male, Swiss Webster mice (22-36 g; Harlan, Indianapolis, IN) were housed in groups of
five in a 12:12-h light/dark cycle with food and water ad libitum. Naïve mice were
randomly assigned to various treatment groups. All procedures using animals were
performed as approved by the IACUC at West Virginia University.
C. Radioligand Binding Assays
Membrane Preparation
Rat brain P2 and rat liver P2 fractions were made from male, Sprague Dawley rats (150200 g; Harlan, Indianapolis, IN). In accordance with IACUC, rats were selected, instead
of mice, in order to use the fewest number of animals without compromising the integrity
of the data. In brief, the animals were first decapitated and the brain minus the cerebellum
were collected and put in ice-cold 10 mM Tris/0.9% NaCl buffer. The tissue is
homogenized in ice-cold in 10 mM Tris-sucrose buffer (0.32 M sucrose in 10 mM Tris,
pH 7.4) with a Potter-Elvehjem homogenizer (5-10 strokes with motor driven Teflon
pestle) using 10 mL buffer per gram of wet tissue with about 3 grams of tissue per batch.
The homogenates were then centrifuged at 1000 x g at 4°C for 10 min and the
supernatants were then taken and centrifuged again at 31,000 x g at 4°C for 15 min. The
pellets from this centrifugation were resuspended in 3 mL of 10 mM Tris (pH 7.4) per
every gram of tissue. The homogenates were then incubated at 25°C for 30 min and then
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centrifuged at 31,000 x g at 4°C for 15 min. The resulting pellets were resuspended in 10
mM (pH 7.4) to achieve a final concentration of 1 gram of tissue per 1.53 mL of buffer.
The homogenates were stored at -80°C in 1 mL aliquots. Protein concentrations were
determined using The Better Bradford Assay Kit (Pierce, Rockford, IL).
Sigma Receptor Binding Assays
The binding affinities of tested compounds for sigma receptors were determined using
two competition binding assay methods. The primary difference between the methods is
tissue type, rat brain P2 membrane was used in the conventional Brandel-method and rat
liver P2 membrane was used in the 96-well plate method. Stock solutions of the ligands
were prepared in deionized water or DMSO. Each compound tested was assayed at 10-12
concentrations to determine binding affinities. Sigma-1 receptors were labeled with 5 nM
[3H](+)-pentazocine; sigma-2 receptors were labeled with 3 nM [3H] DTG in the presence
of 300 nM (+)-pentazocine. Nonspecific binding was determined using 10 µM
haloperidol. The assays were incubated for 120 min at 25° C. Prior to use, filters were
soaked in 0.5% PEI, to decrease non-specific binding, for 30 min. After incubation, assay
solutions were filtered with respective harvesters based on the aforementioned methods
and washed three times with ice-cold 10 mM Tris buffer. Counts were extracted from the
filters with the addition of scintillation cocktail. All competition binding assays on test
ligands had a minimum of three trials completed with each trial being run in duplicates.
In addition to the novel sigma-2 ligands, reference compounds (haloperidol, DTG,
AC927, (+)-pentazocine, and (-)-pentazocine) were tested using the 96-well plate assay.
These compounds were chosen because they are previously profiled sigma ligands with
well-characterized pharmacological properties (Fishback, 2011).
Non-Sigma Receptor Binding Assays
The selectivity for the following monoamine transporters were choose because of
cocaine’s known interactions with them. Dopamine transporters were labeled with
[3H]WIN 35,428 and nonspecific binding was determined using 50 µM cocaine in rat
striatal tissue. Serotonin transporters were labeled with [3H]paroxetine with nonspecific
binding determined using 1.5 µM imipramine in rat brainstem tissue. Lastly,
norepinephrine transporters were labeled with [3H]nisoxetine and nonspecific binding
was determined with 4 µM desipramine in rat cerebral cortical tissue.
Previously established sigma ligands showed to interact with various non-sigma sites,
therefore, the selectivity of the sigma-2 ligands for dopamine (D2), and serotonin (5-HT2)
receptors were determined in rat brain without cerebellum homogenate (Guitart et al.,
2004). While opioid (mu, kappa, delta) receptor binding affinities were determined in
CHO cells transected with human mu (hMOR), kappa (hKOR) and delta (hDOR).
NMDA receptors were labeled with 5 nM [3H]TCP with nonspecific binding determined
with 10 µM cyclazocine. Dopamine receptors were labeled with 5 nM [3H](-) sulpiride
and nonspecific binding was established using 1 µM haloperidol. Furthermore, serotonin
receptors were labeled with 2 nM [3H]ketanserin and nonspecific binding was found
using 1 µM mianserin. Mu receptors were labeled with 1.3 nM [3H]DAMGO, kappa
receptors were labeled with 1.7 nM [3H]U69,593 and delta receptors with 1.2 nM
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[3H]DPDPE. Nonspecific binding for the opioid receptor subtypes was determined using
1 µM DAMGO (mu), 1 µM U69,593 (kappa) and DPDPE (delta). Incubation time was
60 min at 25° C for dopamine and opioid receptor assays. For serotonin receptors, the
assays were incubated for 30 min at 37° C and 60 min at 4° C for NMDA receptor assays.
After incubation, assay solutions were filtered and washed three times with ice-cold 10
mM Tris buffer. Counts were extracted from the filters with the addition of scintillation
cocktail.
D. Cocaine-induced Convulsions
This study was conducted in order to observe the novel sigma-2 ligands’ effects on acute
cocaine toxicity. Attenuation of the convulsions is expected from putative antagonists
while elicitation of cocaine-induced convulsions and/or lethality is expected from
putative agonists.
Cocaine Dose Response
To find a convulsive dose of cocaine, animals (n = 50) were given a pretreatment of
saline followed 15 min later with administration of a varying dose of cocaine (40-70
mg/kg, i.p.) The doses of cocaine chosen for the dose response were based on previous
studies (Xu et al., 2010). The animals were then placed in individual plastic chambers (59
x 43 x 13 cm) and observed for the occurrence of convulsions over a 30 min time period.
Convulsions were operationally defined as a loss of righting reflex for at least 5 s
accompanied by clonic or tonic limb movements and/or popcorn jumping. The number of
animals displaying convulsions was recorded in each experimental group.
Testing for Antagonist and Agonist Effects
First, to observe anticonvulsant effects against cocaine, the animals (n = 125) were given
a 15 min pretreatment of a sigma-2 ligand (0.1-20 mg/kg i.p.) followed by a convulsive
dose of cocaine (70 mg/kg, i.p.) which produced 100% convulsions without lethality.
Next, CM699 was probed for agonist effects based on the observation of lethality with
pretreatment to the 70 mg/kg (i.p.) convulsive dose of cocaine. Here, the challenge dose
of cocaine was varied (40-70 mg/kg, i.p.) in order to observe exacerbation of convulsions
leading to a leftward shift in the cocaine dose-response. After administration of the
dosing regimen, the animals were then placed in individual plastic chambers (59 x 43 x
13 cm) and observed for the occurrence of convulsions over a 30 min time period.
Convulsions were operationally defined as a loss of righting reflex for at least 5 s
accompanied by clonic or tonic limb movements and/or popcorn jumping. The number of
animals displaying convulsions was recorded in each experimental group.
E. Locomotor Activity
This study was performed in order to observe the novel sigma-2 ligands’ effects on
cocaine psychomotor stimulant effects. Attenuation of cocaine-induced locomotor
hyperactivity and no effect on basal locomotor activity is expected from putative
antagonists while exacerbation is expected from putative agonists.
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Cocaine Dose Response
The mice were first acclimated to the testing room for 30 min and then individually to the
Plexiglas testing chambers of the automated activity monitoring system for 30 min (San
Diego Instruments, San Diego, CA). To find a locomotor stimulant dose of cocaine,
animals (n = 38) were administered varying doses of cocaine (0-30 mg/kg, i.p.), used in
previous studies, to determine a dose response curve (McCracken et al., 1999). Total
locomotor activity (ambulatory, fine, and rearing movements) was quantified as the
number of disruptions in the 16 x 16 photobeam grid in the Plexiglas testing chambers.
The dose of cocaine that produced the highest level of locomotor hyperactivity was used
in the subsequent locomotor experiments.
Testing for Antagonist and Agonist Effects
The mice were first acclimated to the testing room for 30 min and then individually to the
Plexiglas testing chambers of the automated activity monitoring system for 30 min (San
Diego Instruments, San Diego, CA). To measure the effects of the sigma-2 ligands alone
and on cocaine-induced locomotor hyperactivity, the mice (n = 144) were administered
(i.p.) a 15 min pretreatment of a sigma-2 compound (0.1-20 mg/kg, i.p.) followed by a
locomotor stimulatory challenge dose of cocaine (30 mg/kg, i.p.; n = 78) or saline (n =
66). Starting ligand pretreatment doses were determined by taking effective doses used in
the convulsion studies, into consideration. While the stimulant dose of cocaine produced
the highest level of locomotor hyperactivity.
F. Data Analysis
All data were analyzed using GraphPad Prism (GraphPad Software Inc., San Diego, CA).
The data from the binding assays were analyzed using a non-linear regression (curve fit)
using the Cheng-Prusoff equation and Kd values were determined in separate saturation
assays. The data from the convulsion studies were analyzed using Fisher’s exact tests.
The data from the locomotor activity studies were analyzed using a one-way analysis of
variance (ANOVA) followed by post-hoc Dunnett’s, for comparison to controls, or
Tukey’s, for pairwise comparisons, tests. Values of p < 0.05 were considered statistically
significant.
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III. RESULTS
A. Sigma and Non-sigma Receptor Binding Affinities
Table 1 summarizes the affinities of CM699, CM398, CM777 and CM775 for sigma-1
and sigma-2 receptors, as well as seven other receptors and transporters in brain
homogenate. All compounds displayed subnanomolar affinities for sigma-2 receptors and
moderate to low affinity for sigma-1 receptors. Specifically, CM699, CM398 and CM777
all had >1000-fold preference for sigma-2 receptors versus sigma-1 receptors and CM775
possessed a >500-fold preference for sigma-2 receptors.
All of the compounds maintained selectivity for sigma-2 receptors versus the non-sigma
sites tested. CM699 and CM398 displayed a >1000-fold and >50-fold preference,
respectively, for sigma-2 receptors over DAT. Furthermore, CM398 and CM775 both
showed >100-fold affinity for sigma-2 receptors versus SERT. CM777 and CM775 had
>50-fold selectivity for sigma-2 over 5-HT2 receptors. All other binding affinities of the
novel compounds to non-sigma sites were negligible. Compared to their high affinity for
sigma-2 receptors, CM699, CM398 and CM777 all displayed 500-fold weaker affinity
for non-sigma sites tested.
Sigma receptors
Ki (nM)

CM699
CM398
CM777
CM775

Monoamine transporters
Ki (nM)

Other neurotransmitter receptors
Ki (nM)

σ1

σ2

DAT

SERT

NET

D2

5-HT2

NMDA

Opioid

16.7
±1.09
560
±8.72
752
±51.4
2270
±187

0.01
± 0.00
0.43
± 0.02
0.66
± 0.01
4.3
± 0.29

131.5
± 1.9
32.9
± 1.9

>1000

>1000

>1000

>1000

>10000

>1000

244.2
± 2.4

>1000

>1000

>1000

>10000

>1000

>1000

>1000

>10000

>10000

>10000

>10000

>1000

445.9
± 3.2

>10000

>1000

>10000

>10000

54.7
± 0.27
249.6
± 4.8

Table 1. Binding affinities of CM699, CM398, CM777 and CM775.
Affinities (Ki values in nanomolar) were determined in brain tissue homogenates with the
exception of opioid receptors in CHO cells. The values represent ±S.E.M. from replicate
assays. Values of >10,000 represent less than 30% displacement of the radioligand at that
concentration.
To determine the correlation between binding affinities of our novel compounds in
addition to the reference compounds tested in brain versus liver tissue, a correlation
analysis was performed (Fig. 2). Table 2 summarizes the affinities of CM699, CM398,
CM775 and five sigma receptor reference compounds (haloperidol, DTG, AC927, (+)pentazocine, and (-)-pentazocine) at sigma-1 and sigma-2 receptors in liver tissue
homogenate. CM777 was not tested. At both sigma-1 and sigma-2 receptors, a significant
correlation was reported between brain and liver homogenate (r2=0.99 and r2=0.99,
respectively).
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Liver Tissue

Haloperidol
DTG
AC927
(+)-Pentazocine
(-)-Pentazocine
CM699
CM398
CM775

σ1
Ki (nM)
3.8
±0.5
28.2
±4.0
44.4
±4.8
8.0
±0.4
11.5
±2.2
21.7
±3.5
388.0
±60.6
2561.3
±242.7

σ2
Ki (nM)
114.0
±7.0
20.2
±6.4
106.7
±6.4
1419.0
±65.3
28.1
±1.5
1.6
±0.3
0.7
±0.2
31.0
±3.5

Brain Tissue
σ1 / σ2
.03
1.4
.41
.01
.41
14
550
82

σ1
Ki (nM)
3.9 a
±0.5
57.4 a
±3.3
61.2 a
±5.6
8.65 a
±0.4
57.2 a
±1.9
16.7
±1.09
560
±8.72
2270
±187

σ2
Ki (nM)
155 a
±2.0
43.3 a
±0.6
384 a
±34.0
1414 a
± 207
108 a
±4.40
0.01
±0.00
0.43
±0.02
4.3
±0.29

σ1 / σ2
.03
1.3
.16
.01
.53
1700
950

Table 2. Binding affinities of sigma reference ligands and CM699, CM398, and
CM775 in liver and brain.
Affinities (Ki values in nanomolar) were determined in liver and brain tissue
homogenates. The values represent ± S.E.M. from replicate assays.

a

Fishback, 2011
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Fig. 3. Correlation plot of sigma receptor binding affinities in brain and liver
membrane.
A, Sigma-1 receptor radioligand binding affinities, CM699, CM398, CM775 and five
reference compounds were correlated in brain and liver tissue (r2=0.99, p<0.0001).
B, Sigma-2 receptor radioligand binding affinities for CM699, CM398, CM775 and five
reference compounds were correlated in brain and liver tissue (r2=0.99, p<0.001).
Ki values represent means determined from a minimum of 3 assays.
B. Cocaine-induced Convulsions
Cocaine Dose Response
Cocaine elicited convulsions in a dose-dependent manner, with 100% of the animals
convulsing at the dose of 70 mg/kg of cocaine (Fig. 4A). While animals administered
saline alone showed 0% convulsions (data not shown). Fisher’s exact test showed
significantly more convulsions at 70 mg/kg of cocaine (###p < 0.001 vs. saline).
Testing for Antagonist and Agonist Effects
Convulsions, caused by a cocaine dose of 70 mg/kg, were attenuated following
pretreatment with CM398 (Fig. 4B; 20 mg/kg, p<0.05) CM777 (Fig. 4C; 10 mg/kg,
p<0.001), and CM775 (Fig. 4D; 20 mg/kg, p<0.05). Conversely, CM699 was unable to
block the cocaine-induced convulsions. Pretreatment with CM699 (10 mg/kg) followed
by 70 mg/kg of cocaine produced 100% convulsions followed by 60% lethality in the
animals (data not shown). Previous studies have shown similar observations with sigma
receptor agonists, leading CM699 to be probed for exacerbation of cocaine convulsions
(Matsumoto et al., 2002; McCracken et al., 1999). Pretreatment with CM699 (5 mg/kg)
prior to a non-convulsive dose of cocaine (50 mg/kg) caused convulsions in 50% of the
mice (Fig. 5; p<0.01). Pretreatment with CM699 (5 mg/kg) prior to a convulsive dose of
cocaine (60 mg/kg) increased the occurrence of convulsions by 50% in the mice
(p<0.05). The ED50 for cocaine alone was 62 mg/kg while CM699 pretreatment (1 and 5
mg/kg) to a dose of cocaine displayed ED50 values of 55 mg/kg and 48 mg/kg,
respectively.

###
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Fig. 4. The effects of cocaine, CM398, CM777, and CM775 on convulsions.
Male, Swiss Webster mice were pretreated (i.p.) with saline, CM398, CM777, or CM775
prior to cocaine. A, administration of cocaine (40-70 mg/kg, i.p.) produced a dosedependent increase in the percentage of animals displaying convulsions. B, Pretreatment
of CM398 (0-20 mg/kg, i.p.) prior to a convulsive dose of cocaine (70 mg/kg, i.p.) caused
a significant reduction in the occurrence of convulsions. C, Pretreatment of CM777 (0-10
mg/kg, i.p.) prior to a convulsive dose of cocaine (70 mg/kg, i.p.) caused a dosedependent decrease in the occurrence of convulsions. D, Pretreatment of CM775 (0-20
mg/kg, i.p.) prior to a convulsive dose of cocaine (70 mg/kg, i.p.) produced a dosedependent decrease in the occurrence of convulsions. ###p<0.001 vs. saline; *p<0.05,
***p<0.001 vs. cocaine (70 mg/kg); Fisher’s exact test.

Fig. 5. The effects of cocaine and CM699 on convulsions.
Male, Swiss Webster mice administered cocaine alone (no CM699 pretreatments)
showed either no or lower numbers of convulsions. Male, Swiss Webster mice pretreated
(i.p.) with CM699 (5 mg/kg) prior to a non-convulsive dose of cocaine (50 mg/kg, i.p.)
significantly caused 50% of the animals to convulse. While pretreatment of CM699 (5
mg/kg, i.p.) prior to a convulsive dose of cocaine (60 mg/kg, i.p.) resulted in a significant
increase, from 30% to 80%, of convulsions. *p<0.05 vs. cocaine (60 mg/kg), **p<0.01
vs. cocaine (50 mg/kg); Fisher’s exact test.
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C. Locomotor Activity
Cocaine Dose Response
Cocaine dose-dependently increased locomotor activity (Fig. 6A). One-way ANOVA
showed significant differences between all groups tested (F(3,31) = 8.61, p < 0.001).
Post-hoc Dunnett’s test confirmed significant increases in locomotor activity at 20 and 30
mg/kg (q = 4.72, p < 0.05; q = 6.45, p < 0.001, respectively).
Testing for Antagonist Effects
Pretreatment with CM398 (Fig. 6B), CM777 (Fig. 6D) and CM775 (Fig. 6F) prior to a
locomotor stimulant dose of cocaine (30 mg/kg) significantly attenuated cocaine-induced
hyperactivity. One-way ANOVA showed significant differences between all groups
tested for CM398, CM777 and CM775 (F(3,36) = 5.09, p < 0.01; F(3,25) = 7.87, p <
0.001; F(3,37) = 6.36, p < 0.001, respectively). Post-hoc Dunnett’s multiple comparisons
test confirmed a significant protective effect for each compound at the following doses:
20 mg/kg of CM398 (q = 5.42, p < 0.01) and CM777 (q = 6.86, p < 0.001), 1 mg/kg and
10 mg/kg of CM775 (q = 4.06, p < 0.05; q = 6.09, p < 0.001, respectively). Each
compound tested displayed no significant effects on its own at any of the doses
administered: CM398 (Fig. 6C, F(3,31) =.056, p > 0.05), CM775 (Fig. 6E, F(3,37) =
2.86, p > 0.05) and CM777 (Fig. 6G, F(3,23) = 2.57, p > 0.05).
Since the ability of the compounds’ to block stimulant locomotor hyperactivity was being
examined in these experiments and CM699 displayed agonistic properties in the
convulsion studies, it was excluded from these tests.
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Fig. 6. The effects of cocaine, CM398, CM777, and CM775 on locomotor activity.
Male, Swiss Webster mice were pretreated (i.p.) with saline, CM398, CM777, or CM775
prior to a stimulant dose of cocaine. A, Administration of cocaine (0-30 mg/kg, i.p.)
produced a dose-dependent increase in locomotor activity. B, Pretreatment with CM398
(0-20 mg/kg, i.p.) significantly attenuated cocaine-induced hyperactivity. C, CM398 (020 mg/kg, i.p.) alone produced no significant effect on locomotor activity. D,
Pretreatment with CM777 (0-20 mg/kg, i.p.) significantly attenuated cocaine-induced
hyperactivity. E, CM777 (0-20 mg/kg, i.p.) alone produced no significant effect on
locomotor activity. F, Pretreatment with CM775 (0-10 mg/kg, i.p.) significantly
attenuated cocaine-induced hyperactivity in a dose dependent manner G, CM775 (0-10
mg/kg, i.p.) alone produced no significant effect on locomotor activity. $$$p<0.001 vs.
saline; *p<0.05, **p<0.01,***p<0.001 vs. cocaine (30 mg/kg); post-hoc Dunnet’s.
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IV. DISCUSSION
The binding data in this study revealed the novel compounds, CM699, CM398, CM777
and CM775, to have high affinity and are selective for sigma-2 receptors. These
compounds have not only exhibited selectivity for sigma-2 receptors versus sigma-1
receptors, but also versus other non-sigma receptor sites, allowing their actions to be
more confidently attributed to interaction with sigma-2 receptors. Previous compounds
characterized as sigma-2 receptor ligand prove inadequate tools for studying the receptor.
One reason is some of these compounds’ display poor or moderate binding affinities (Ki)
for sigma-2 receptors. This also holds true for their selectivity for sigma-2 versus sigma-1
receptors. Additionally, the selectivity of the ligands for sigma-2 receptors against nonsigma sites is also largely problematic, with many of them exhibiting considerable
affinities for various non-sigma sites. Moreover, numerous numbers of these sigma-2
receptor ligands do not even have, or report, data regarding their binding affinities to nonsigma sites. Due to the aforementioned issues of past sigma-2 receptor compounds,
CM699, CM398, CM777 and CM775 are the best-suited pharmacological tools for
studying the role of sigma-2 receptors in psychostimulant actions to date.
The binding affinities exhibited of the compounds’ for both sigma subtypes in brain and
liver tissue exhibited slight variations when compared. It is important to note that when
comparing different data sets of ligand binding affinities at sigma-2 receptors variations
in data can be seen. A putative explanation is because of sigma-2 receptor localization in
lipid rafts, which can impact the binding affinity of ligands for sigma-2 receptors. This is
thought to be a result of variations in lipid compositions and associated proteins across
different lipid rafts in tissues (Fishback, 2011). Yet, the data in this study exhibited strong
correlations of the affinities for each receptor subtype in both liver and brain membrane
with rank order being conserved. Thus, the results obtained are comparable at sigma-1
and sigma-2 receptors in both brain and liver membrane.
In the present study, behavioral tests showed the ability of CM398, CM777 and CM775
to attenuate cocaine-induced acute toxic and stimulant effects, while the CM699,
exacerbated cocaine’s acute toxic effects. Though the mechanism of action is unclear, it
has been hypothesized to be a result of dopamine release modulation (Nuwayhid and
Werling, 2006). The ability of CM398, CM777 and CM775 to attenuate cocaine-induced
convulsions helped address the ‘statement of problem’ presented in this study. The higher
selectivity and affinity of these compounds, versus previously proposed selective ligands,
for sigma-2 provides more compelling support for the involvement of sigma-2 receptors
in the convulsant actions of cocaine. CM777, compared to CM398 and CM775, showed
more potent effect by protecting against the most convulsions at the lowest dose. A
potential explanation is the better affinity of CM777 for 5-HT2 , which has shown anticocaine effects when antagonized (McCracken et al., 1999). However, CM156, a
previously characterized sigma ligand, with a similar sigma-2 receptor affinity to CM777
but much lower affinity for 5-HT2 exhibited related protective effects against cocaineinduced convulsions (Xu et al., 2010). Therefore, CM777’s interaction with 5-HT2 is
unlikely to be the main mechanism of the compound’s protective activity. Furthermore,
CM156 has a >-500-fold affinity for sigma-1 receptors compared to CM777 but
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displayed a comparable dose response curve for cocaine-induced convulsions (Xu et al.,
2010). This supports sigma-2 receptors’ role in CM777 anticonvulsant effects.
Sigma-1 receptor agonists are thought to serve a significant role in exacerbating cocaineinduced convulsions (Katz et al., 2011). Yet, a lack of information and understanding
exists regarding the relevance of sigma-2 receptors in exacerbating cocaine convulsions,
particularly compared to sigma-1 receptors (Matsumoto et al., 2001a). This is largely
ascribed to a paucity in selective sigma receptor agonists, particularly for sigma-2. In the
present study, pretreatment with CM699 in mice shifted the dose-response curve for
cocaine-induced convulsions to the left. Furthermore, pretreatment with CM699
worsened cocaine toxicity, with some mice dying after administration of non-lethal doses
of cocaine. These results reflect similar effects observed with the well-established sigma
receptor agonist DTG (Matsumoto et al., 2002; McCracken et al., 1999). Though DTG is
not selective for a particular sigma receptor subtype, it does serve as a comparison for
putative sigma receptor agonists. Yet, since CM699 was unable to produce convulsions
when administered alone and indicate CM699 similarity to positive allosteric modulators.
Being that, to date, CM699 is one of the highest sigma-2 selective compounds (versus
sigma-1), the data obtained suggests a specific contribution of this receptor subtype in
worsening cocaine-induced convulsions. To confirm the results and effects seen with
CM699, it is important to develop additional highly selective sigma-2, versus sigma-1,
receptor putative agonists to use as pharmacological tools.
The ability of CM398, CM777 and CM775 to significantly alleviate cocaine-induced
locomotor hyperactivity is congruent with previous studies implicating the sigma-2
subtype in mediating locomotion (Walker et al., 1993). Though the precise mechanism of
sigma-2 in cocaine-induced hyperactivity remains unclear; it is thought that the receptor
modulates dopamine in cocaine’s locomotor actions (Walker et al 1993; Bastianetto et al.,
1995; Nuwayhid and Werling, 2006; Garces-Ramirez et al., 2011). Fortunately, the
compounds in the present study possess some of the highest affinities with the highest
selectivity for the sigma-2 subtype and will be useful pharmacological tools in further
characterizing sigma-2 effects and functions. Future studies to further distinguish
functionality of the novel sigma-2 selective ligands should be performed. Specifically, in
vivo experiments looking at the effects of the sigma-2 ligands on apoptosis can help
distinguish antagonistic/agonistic properties (Crawford and Bowen, 2002).
Though these ligands provide some of the best-suited pharmacological tools for studying
sigma-2 receptors limitations still remain. Due to the involvement of sigma-2 receptors
regulating cell life and death, this could have impacted some of the outcomes in the
behavioral study, unknowingly. Additionally, a substantial drawback is the inability to
confirm the effects on cocaine-induced behaviors seen with the selective sigma-2 ligands
with knockdown and/or knockout of sigma-2 receptors. Regrettably, until this receptor
subtype is sequenced this limitation will remain problematic. Even with that being said,
the current study still provides the most compelling evidence of sigma-2 receptors’
involvement and specific contribution in the acute toxic and stimulant effects of cocaine
to date. Further studies of the receptor subtype are needed better characterize its ability to
modulate the actions of psychostimulants, and consequently, its potential as a therapeutic
target in the development of pharmacotherapies for illicit drug use and abuse.
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